secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015726
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q3 net loss $15M; FDA approved Emrosi on Nov 4; cosibelimab PDUFA Dec 28
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $15.0M ($0.76/shr) vs $7.1M loss in Q3 2023.
- Consolidated net revenue $14.6M (all from dermatology products); Q3 2023 revenue $34.8M included $19M license fee.
- Cash and equivalents $58.9M as of Sep 30, 2024, down $22M YTD; included $25.6M at Fortress and private subs.
- Paused Series A preferred dividends in July 2024, deferring ~$0.7M cash/month; new $35M Oaktree loan terms.
- FDA approval of Emrosi on Nov 4; cosibelimab PDUFA date Dec 28; Checkpoint raised $9.2M in Nov warrant exercises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/0001558370-24-015726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer